These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3471751)

  • 1. The pharmacokinetics of enoxacin in elderly patients.
    Wise R; Baker SL; Misra M; Griggs D
    J Antimicrob Chemother; 1987 Mar; 19(3):343-50. PubMed ID: 3471751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1986; 14 Suppl 3():S203-8. PubMed ID: 3463543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
    Wise R; Lockley R; Webberly M; Adhami ZN
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():75-81. PubMed ID: 6238932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term treatment and clinical evaluation of enoxacin in complicated urinary tract infections].
    Washida H; Sakagami H; Iwase Y; Sasaki S
    Hinyokika Kiyo; 1987 Sep; 33(9):1508-12. PubMed ID: 3481218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of enoxacin and co-trimoxazole in the treatment of patients with complicated urinary tract infections.
    Cox CE
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():113-8. PubMed ID: 3258862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.
    Bailey RR; Walker RJ; Lynn KL; Donaldson IM; Peddie BA; Dobbs BR
    Br J Clin Pharmacol; 1988 Feb; 25(2):223-8. PubMed ID: 3162809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxacin for the treatment of urinary tract infection.
    Bailey RR; Peddie BA
    N Z Med J; 1985 Apr; 98(777):286-8. PubMed ID: 3857511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
    Wolf R; Eberl R; Dunky A; Mertz N; Chang T; Goulet JR; Latts J
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():63-9. PubMed ID: 6389476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva.
    Vree TB; Baars AM; Wijnands WJ
    J Chromatogr; 1985 Oct; 343(2):449-54. PubMed ID: 3864785
    [No Abstract]   [Full Text] [Related]  

  • 11. A double-blind comparative trial of short-term orally administered enoxacin in the prevention of urinary infection after elective transurethral prostatectomy: a clinical and pharmacokinetic study.
    Desai KM; Abrams PH; White LO
    J Urol; 1988 Jun; 139(6):1232-4. PubMed ID: 2453683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tissue penetration of enoxacin.
    Wise R; Lockley R; Dent J; Webberly M
    Antimicrob Agents Chemother; 1984 Jul; 26(1):17-9. PubMed ID: 6591851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
    Davies BI; Maesen FP; Teengs JP
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():83-9. PubMed ID: 6594325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxacin treatment of urinary tract infections in elderly patients.
    Huttunen M; Kunnas K; Saloranta P
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():105-11. PubMed ID: 3162900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxacin treatment of urinary tract infections.
    Thomas MG; Ellis-Pegler RB
    J Antimicrob Chemother; 1985 Jun; 15(6):759-63. PubMed ID: 3861605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of enoxacin and norfloxacin in patients with cystitis.
    Yamamoto M; Nagai T; Takaba H; Hashimoto J; Miyake K
    Hinyokika Kiyo; 1987 Dec; 33(12):2141-4. PubMed ID: 3482344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    Dobbs BR; Gazeley LR; Stewart IA; Edwards IR
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():61-6. PubMed ID: 3162903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.